{
    "clinical_study": {
        "@rank": "99085", 
        "arm_group": [
            {
                "arm_group_label": "Pre-Phase Arm", 
                "arm_group_type": "Experimental", 
                "description": "They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for \u2265 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol."
            }, 
            {
                "arm_group_label": "Geriatric Assessment (GA) only arm", 
                "arm_group_type": "Experimental", 
                "description": "Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the ability of a largely self-administered geriatric assessment\n      (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients \u226560 years old receiving\n      chemotherapy or chemoimmunotherapy."
        }, 
        "brief_title": "Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non Hodgkin Lymphoma (NHL)", 
            "Diffuse Large B-cell Lymphoma (DLBCL)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects meeting the following criteria will be eligible for enrollment in the study\n        (unless excluded):\n\n          -  \u226560 years old\n\n          -  Pathologically confirmed NHL.\n\n          -  Must meet criteria for initiation of treatment; consisting of:\n\n          -  Aggressive histology, or\n\n          -  Indolent histology with one of the following markers of large tumor burden (67):\n\n          -  Any nodal or extranodal tumor mass \u22657cm in greatest dimension\n\n          -  \u22653 nodal masses that are each \u22653 cm in greatest dimension\n\n          -  Systemic symptoms\n\n          -  Cytopenias (leukocytes <1 \u00d7 109/L and/or platelets ,100 \u00d7 109/L)\n\n          -  Substantial splenomegaly\n\n          -  Serous effusion (plural effusion or peritoneal ascites)\n\n          -  Orbital or epidural involvement\n\n          -  Ureteral compression\n\n          -  Leukemic phase (malignant cells \u22655 x 109/L)\n\n          -  Must be starting a new chemotherapy regimen\n\n          -  Fluent in English (because not all components of the GA have been validated in other\n             languages)\n\n          -  Able to provide informed consent\n\n        In addition to the above, subjects meeting the following criteria will be enrolled in the\n        pre-phase arm of the study, until the accrual target for that arm is reached:\n\n          -  Age \u2265 70 years OR KPS \u2264 70\n\n          -  Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or\n             antecedent indolent lymphoma.\n\n          -  Previously untreated for DLBCL\n\n          -  Intended initial treatment to include \u22652 cycles of R-CHOP, R-EPOCH or R-CEPP using\n             standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14\n             days or every 21 days. (4, 70)\n\n        Exclusion Criteria:\n\n        Subjects meeting the following criteria will be excluded from enrollment in the study:\n\n          -  Enrollment in a Phase I trial\n\n          -  Previously enrollment in this study\n\n          -  Patients scoring \u2265 11 on the BOMC (implying cognitive impairment) will be excluded\n             since their ability to reliably complete the questionnaire will be in doubt Subjects\n             meeting the following criteria will be excluded from enrollment in the pre-phase arm\n             of the study, but may be included in the GA only arm.\n\n          -  Contraindication to use of rituximab or prednisone including:\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Systemic fungal infection\n\n          -  Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B\n             surface antigen or viral DNA by PCR analysis) will be excluded. Patients with\n             evidence of past infection without active viremia (i.e. positive hepatitis B core\n             antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will\n             be treated with entecavir as per institutional guidelines and may be included in the\n             study.\n\n          -  History of any serious adverse reaction to either a corticosteroid or rituximab not\n             including rituximab infusion reactions \u2264 Grade 3.\n\n          -  Patients enrolled on another clinical trial which prohibits the use of pre-phase\n             therapy or any of its components."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829958", 
            "org_study_id": "13-028"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pre-Phase Arm", 
                "intervention_name": "rituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pre-Phase Arm", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Pre-Phase Arm", 
                    "Geriatric Assessment (GA) only arm"
                ], 
                "intervention_name": "Geriatric Assessment", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisone", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Geriatric", 
            "Toxicity", 
            "rituximab", 
            "prednisone", 
            "Comprehensive Geriatric Assessment (CGA)", 
            "13-028"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Paul Hamlin, MD", 
                    "phone": "212-639-6143"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07920"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Basking Ridge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Hamlin, MD", 
                    "phone": "212-639-6143"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Hamlin, MD", 
                    "phone": "212-639-6143"
                }, 
                "contact_backup": {
                    "last_name": "Andrew Zelenetz, MD, PhD", 
                    "phone": "212-639-2656"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Paul Hamlin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Hamlin, MD", 
                    "phone": "212-639-6143"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11570"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Hamlin, MD", 
                    "phone": "212-639-6143"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy", 
        "overall_contact": {
            "last_name": "Paul Hamlin, MD", 
            "phone": "212-639-6143"
        }, 
        "overall_contact_backup": {
            "last_name": "Andrew Zelenetz, MD, PhD", 
            "phone": "212-639-2656"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Paul Hamlin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity \u226480% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading", 
            "measure": "Toxicity Assessment", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829958"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}